Search alternatives:
significant challenge » significant changes (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
decrease » decreased (Expand Search), increase (Expand Search)
significant challenge » significant changes (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
decrease » decreased (Expand Search), increase (Expand Search)
-
41
-
42
Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges.
Published 2020“…(B) Tactile sensitivity in sensitized mice preventatively treated with imatinib or NT and then 10 daily MI challenges. Results reported as mean ± SEM of the percent decrease from baseline in the withdrawal threshold for each treatment group, n = 18/treatment group. …”
-
43
-
44
-
45
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
46
-
47
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
48
-
49
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
50
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60